AU2005262050B2 - Use of L-carnitine and glucose for the treatment of cardiovascular diseases - Google Patents

Use of L-carnitine and glucose for the treatment of cardiovascular diseases Download PDF

Info

Publication number
AU2005262050B2
AU2005262050B2 AU2005262050A AU2005262050A AU2005262050B2 AU 2005262050 B2 AU2005262050 B2 AU 2005262050B2 AU 2005262050 A AU2005262050 A AU 2005262050A AU 2005262050 A AU2005262050 A AU 2005262050A AU 2005262050 B2 AU2005262050 B2 AU 2005262050B2
Authority
AU
Australia
Prior art keywords
carnitine
acid
infarction
glucose
glucose solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005262050A
Other languages
English (en)
Other versions
AU2005262050A1 (en
Inventor
Aleardo Koverech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of AU2005262050A1 publication Critical patent/AU2005262050A1/en
Application granted granted Critical
Publication of AU2005262050B2 publication Critical patent/AU2005262050B2/en
Assigned to Alfasigma S.p.A reassignment Alfasigma S.p.A Request for Assignment Assignors: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005262050A 2004-07-13 2005-06-21 Use of L-carnitine and glucose for the treatment of cardiovascular diseases Ceased AU2005262050B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
ITRM2004A000346 2004-07-13
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
AU2005262050A1 AU2005262050A1 (en) 2006-01-19
AU2005262050B2 true AU2005262050B2 (en) 2011-02-24

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005262050A Ceased AU2005262050B2 (en) 2004-07-13 2005-06-21 Use of L-carnitine and glucose for the treatment of cardiovascular diseases

Country Status (21)

Country Link
US (2) US7879908B2 (enExample)
EP (1) EP1773314B1 (enExample)
JP (1) JP5230195B2 (enExample)
KR (1) KR101296479B1 (enExample)
CN (2) CN102349923B (enExample)
AT (1) ATE542529T1 (enExample)
AU (1) AU2005262050B2 (enExample)
BR (1) BRPI0513303A8 (enExample)
CA (1) CA2569888C (enExample)
CY (1) CY1112686T1 (enExample)
DK (1) DK1773314T3 (enExample)
ES (1) ES2380913T3 (enExample)
HR (1) HRP20120178T1 (enExample)
IT (1) ITRM20040346A1 (enExample)
ME (1) ME01345B (enExample)
MX (1) MXPA06014665A (enExample)
PL (1) PL1773314T3 (enExample)
PT (1) PT1773314E (enExample)
RS (1) RS52253B (enExample)
SI (1) SI1773314T1 (enExample)
WO (1) WO2006005415A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
AU1295700A (en) * 1998-11-26 2000-06-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
MXPA02003635A (es) * 1999-10-11 2002-10-23 Sigma Tau Ind Farmaceuti Uso de l-carnitina y sus derivados de alcanoilo como agentes osmoticos en soluciones para uso medico.
JP4674046B2 (ja) * 2002-04-01 2011-04-20 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ グルコース利用を刺激する化合物および使用方法
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARSENIAN MICHAEL A; NEW PETER S; CAFASSO CYNTHIA M: AMERICAN JOURNAL OF CARDIOLOGY, vol. 78, no. 4, 1996, pages 476-479. *
GRANDI M; PEDERZOLI S; SACCHETTI C: "Effect of acute carnitine administration on glucose insulin metabolism in healthy subjects" INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, vol. 17, no. 4,1997, pages 143-147 *

Also Published As

Publication number Publication date
CA2569888C (en) 2013-08-13
US8394854B2 (en) 2013-03-12
CN101087602B (zh) 2011-09-14
CN102349923A (zh) 2012-02-15
ITRM20040346A1 (it) 2004-10-13
JP5230195B2 (ja) 2013-07-10
PT1773314E (pt) 2012-03-29
KR20070039541A (ko) 2007-04-12
ME01345B (me) 2012-10-31
PL1773314T3 (pl) 2012-06-29
DK1773314T3 (da) 2012-05-07
US20110086917A1 (en) 2011-04-14
WO2006005415A2 (en) 2006-01-19
HK1113542A1 (en) 2008-10-10
ATE542529T1 (de) 2012-02-15
EP1773314A2 (en) 2007-04-18
HRP20120178T1 (hr) 2012-05-31
US7879908B2 (en) 2011-02-01
RS52253B (sr) 2012-10-31
AU2005262050A1 (en) 2006-01-19
WO2006005415A3 (en) 2006-05-26
HK1166003A1 (zh) 2012-10-19
US20070207970A1 (en) 2007-09-06
EP1773314B1 (en) 2012-01-25
KR101296479B1 (ko) 2013-08-13
BRPI0513303A (pt) 2008-05-06
BRPI0513303A8 (pt) 2017-12-26
CA2569888A1 (en) 2006-01-19
CN101087602A (zh) 2007-12-12
CN102349923B (zh) 2016-04-27
CY1112686T1 (el) 2016-02-10
MXPA06014665A (es) 2007-03-12
SI1773314T1 (sl) 2012-04-30
JP2008517872A (ja) 2008-05-29
ES2380913T3 (es) 2012-05-21

Similar Documents

Publication Publication Date Title
AU2010202396A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
US8394854B2 (en) Use of L-carnitine for the treatment of cardiovascular diseases
HUP0400060A2 (hu) Acetil-L-karnitin alkalmazása biotinnal együtt, II típusú, inzulinrezisztens diabétesz mellituszban szenvedő betegek kezelésére
HK1113542B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1166003B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
US20090042983A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
HK1132174A (en) Use of l-carnitine for the treatment of cardiovascular diseases
JP2008517872A5 (enExample)
HK1085929A (en) Use of l-carnitine for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALFASIGMA S.P.A

Free format text: FORMER OWNER(S): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired